A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
AffiliationBaylor College of Medicine, Houston, Texas, USA.
MetadataShow full item record
AbstractThis article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease.
CitationA roundtable discussion of aromatase inhibitors as therapy for breast cancer., 9 (3):213-22 Breast J
JournalThe Breast Journal
- The role of aromatase inhibitors in the treatment of metastatic breast cancer.
- Authors: Mouridsen H, Gershanovich M
- Issue date: 2003 Aug
- The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
- Authors: Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G
- Issue date: 2004 Oct 1
- Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
- Authors: Jahanzeb M
- Issue date: 2007 Aug
- Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
- Authors: Mouridsen HT, Robert NJ
- Issue date: 2005 Aug 24
- [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
- Authors: van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW
- Issue date: 2006 Dec 30